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Control of cellular metabolism is critical for efficient cell function, although little is known
about the interplay between cell subset–specific metabolites in situ, especially in the tumor
setting. Here, we determined how a macrophage-specific (Mj-specific) metabolite, itaconic
acid, can regulate tumor progression in the peritoneum. We show that peritoneal tumors
(B16 melanoma or ID8 ovarian carcinoma) elicited a fatty acid oxidation–mediated increase
in oxidative phosphorylation (OXPHOS) and glycolysis in peritoneal tissue–resident
macrophages (pResMj). Unbiased metabolomics identified itaconic acid, the product of
immune-responsive gene 1–mediated (Irg1-mediated) catabolism of mitochondrial cis-
aconitate, among the most highly upregulated metabolites in pResMj of tumor-bearing
mice. Administration of lentivirally encoded Irg1 shRNA significantly reduced peritoneal
tumors. This resulted in reductions in OXPHOS and OXPHOS-driven production of ROS in
pResMj and ROS-mediated MAPK activation in tumor cells. Our findings demonstrate that
tumors profoundly alter pResMj metabolism, leading to the production of itaconic acid,
which potentiates tumor growth. Monocytes isolated from ovarian carcinoma patients’
ascites fluid expressed significantly elevated levels of IRG1. Therefore, IRG1 in pResMj
represents a potential therapeutic target for peritoneal tumors.
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Introduction
The peritoneal cavity is a frequent site of tumor development 
and metastasis. Ovarian epithelial cancer often spreads to the 
peritoneal cavity and is treated similarly to primary peritoneal 
cancer (1). The peritoneal cavity is also home to a heteroge-
neous population of peritoneal tissue–resident macrophages 
(pResMϕ) that arise from hematopoietic progenitors and play 
important roles in homeostasis and immune surveillance (2, 3). 
There is clearly the potential for extensive crosstalk between 
tumor cells and pResMϕ within the peritoneal cavity. We 
hypothesized that peritoneal tumors might profoundly influ-
ence the metabolism, and therefore the function, of pResMϕ 
and specifically sought to characterize those metabolic alter-
ations that in turn regulate tumor progression.
Although Mϕ can mediate important antitumor responses, 
there is considerable evidence for their role in promoting the initi-
ation, growth, and metastatic spread of many tumors. The ability 
of Mϕ to produce immunosuppressive cytokines and angiogenic 
factors as well as promote tumor growth has been well described 
(4). In the peritoneum, Mϕ depletion can reduce tumor progres-
sion, metastasis (5), and ascites fluid formation (6). Mϕ-targeted 
therapies are thus promising strategies for the treatment of 
ovarian carcinoma and peritoneal tumors.
Although tumor metabolism has been well studied, it is 
important to define the effects of host-tumor interactions on 
immune cell metabolism when metabolism-based therapies are 
used. Tumors have long been known to have high glycolytic rates, 
as they consume large amounts of glucose and release metabolic 
products of glycolysis. Glycolytic tumors have been proposed to 
metabolically restrict T cells, in part by outcompeting them for 
nutrients such as glucose (7). Moreover, tumor-derived metab-
olites, such as lactic acid, have been implicated in polarizing Mϕ 
toward a tumor-promoting phenotype, characterized by high lev-
els of VEGF and arginase (8). Mϕ polarization is closely linked to 
metabolic programming, with alterations in key signaling path-
ways underlying distinct utilization modes of glucose metabolism 
(9–14). Classically activated Mϕ exhibit increases in glycolysis 
mediated through the AKT/mTOR/HIF1α pathway to regulate the 
inflammatory phenotype. In contrast, alternatively activated Mϕ 
have a vastly different metabolic and inflammatory profile pro-
moted by increased oxidative phosphorylation (OXPHOS). Given 
that cellular metabolism is critical for the regulation of the Mϕ 
phenotype, tumor-mediated alterations in the expression of Mϕ 
metabolites clearly have the potential to underlie important dif-
ferences in the effector function of pResMϕ.
Itaconate is among the most selectively and highly upregu-
lated metabolites in classically activated Mϕ (13, 15, 16). Itaconate 
mediates antimicrobial functions in Mϕ by inhibiting isocitrate 
lyase, an enzyme of the glyoxylate shunt used as a bacterial survival 
mechanism (17). Recently, mitochondria-associated itaconate has 
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strates that itaconate promotes tumor growth via OXPHOS-driven 
ROS expression in resident Mϕ and concomitant ROS-mediated 
MAPK activation in tumor cells. Our data suggest that metabolic 
targeting of IRG1 and itaconate in Mϕ may be effective for the 
control of ROS levels and ROS-driven tumor progression. An 
advantage of our approach is the feasibility of specifically target-
ing resident Mϕ–associated itaconate and ROS for efficient control 
of peritoneal tumors.
Results
Resident Mϕ mediate protumor effects in the peritoneum. Hypothe-
sizing that progressing tumors extensively interact with pResMϕ, 
we first compared macrophages (Mϕ) from naive and tumor- 
bearing mice. F4/80+ Mϕ from peritoneal lavages could be sepa-
rated into 2 populations on the basis of their relative levels of F4/ 
80 and CD49f expression (Figure 1A). The 2 Mϕ populations are 
consistent with larger (LPM) and smaller (SPM) pResMϕ popula-
tions that have been described previously (2, 30). The relative pro-
portion of LPMs and SPMs was similar between control mice and 
mice bearing peritoneal tumors, although the overall frequency 
of F4/80+ Mϕ was increased in tumor-bearing mice (Figure 1B and 
Supplemental Figures 1, A–D; supplemental material available 
online with this article; https://doi.org/10.1172/JCI99169DS1), 
with the total number of leukocytes remaining similar between 
control and tumor-bearing mice. To further characterize pResMϕ, 
we evaluated their expression of Gata-binding factor 6 (Gata6), a 
transcription factor shown to be critical for their phenotype (31, 
32). Gata6 mRNA (Figure 1C) and protein expression levels were 
emerged as an important metabolic regulator of Mϕ function by 
regulating the glycolytic pathway and promoting succinate accu-
mulation during mitochondrial respiration (18, 19). Mammalian 
production of itaconate, or itaconic acid, is catalyzed by immune- 
responsive gene 1 (Irg1), which is transcriptionally regulated by 
IFN-γ, TNF-α, and LPS stimulation (20, 21). IRG1 catabolizes fatty 
acid–derived metabolites, which are necessary energy substrates 
for OXPHOS in Mϕ and OXPHOS-associated ROS production by 
mitochondria (14, 22–24). The IRG1 product itaconate thus links 
metabolism with proinflammatory processes and ROS production 
in Mϕ through alterations in fatty acid oxidation and OXPHOS.
ROS encompass a wide range of molecules such as hydro-
gen peroxide, superoxide, hydroxyl radicals, and peroxynitrite. 
In addition to serving as a critical component of Mϕ bactericidal 
activity, ROS production can have profound effects on inflam-
matory responses and tumor progression. ROS activate numer-
ous transcription factors (e.g., NF-κB, HIF1α, STAT3, and AP-1), 
resulting in a complex association between ROS expression and 
tumor progression (25–27). Although ROS are a critical compo-
nent of many antitumor responses, ROS expression has also been 
associated with the promotion of tumor cell growth and survival, 
in part through enhanced expression and activation of NF-κB and 
MAPK (26, 28, 29).
In this study, we demonstrate that itaconate is among the most 
highly upregulated metabolites in pResMϕ from tumor-bearing 
mice and that an increase in its levels plays an important role in 
tumor progression. Targeted blockade of tumor-induced itacon-
ate in pResMϕ using a lentivirus-based shRNA approach demon-
Figure 1. Characterization of peritoneal leukocytes from tumor-bearing hosts. Flow cytometric analysis was performed on the peritoneal lavage cells 
from (A) naive and (B) B16 tumor–bearing mice. Among F4/80-sorted leukocytes, Gata6 expression was evaluated by (C) qPCR and (D) intracellular flow 
cytometry. Flow cytometric plots are representative of 6 samples (2 experiments each consisting of triplicate samples). The dotted lines represent isotype 
control staining. (E) B16 tumor burden was quantified in WT or Rag–/– mice that received control or clodronate liposomes on day 2 (after tumor) or day 0 
(before tumor) (n ≥5). *P < 0.05, **P < 0.01, and ***P < 0.001, by ANOVA with Tukey’s multiple comparisons test.  (F) F4/80-sorted Mϕ were evaluated by 
qPCR for M2 (left) and M1 (right) prototypic gene expression. Triplicate samples were evaluated, with one of the no-tumor samples set to 1.0 as a reference 
point (heatmaps depict log2-transformed, relative-based results of gene expression; all genes shown were significantly altered in the B16 group to at least 
P < 0.05 as compared with the no-tumor group; unpaired Student’s t test). Data represent the mean ± SEM.
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potential. The protumor phenotype of resident Mϕ could not be 
attributed to a shift between pro- and antiinflammatory phenotypes. 
Although arginase 1 (Arg1) and Vegf increased, the expression of 
most prototypically protumor genes we evaluated was decreased in 
cells from tumor-bearing mice (Figure 1F, left), with a concomitant 
increase in all proinflammatory genes evaluated (Figure 1F, right). 
These data indicate that pResMϕ exhibit a tumor-promoting pheno-
type that cannot be ascribed to a generalized skewing in the expres-
sion of prototypic immunosuppressive and tumor-promoting mole-
cules. Indeed, it has been suggested that classifying Mϕ as polarized 
and ascribing Mϕ function on the basis of pro- and antiinflammatory 
gene expression is an oversimplification and that consideration of 
gene function is more meaningful (33).
The metabolism of resident Mϕ from tumor-bearing mice is 
increased as a result of fatty acid oxidation. We hypothesized that 
metabolic alterations in pResMϕ may underlie their protumor phe-
notype. We therefore evaluated the extracellular flux of pResMϕ 
isolated from control and tumor-bearing mice. pResMϕ from mice 
bearing peritoneal B16 tumors (i.p. inoculation) had dramatically 
elevated basal and maximal oxygen consumption rates (OCRs) 
(Figure 2A) and extracellular acidification rates (ECARs) (Figure 
2B) as compared with those of control mice or mice inoculated 
with B16 tumors via distant routes (i.v. or s.c.). This suggests that 
increased pResMϕ metabolism is locally modulated by perito-
neal tumors. We observed similar results using the ID8 ovarian 
carcinoma cell line (Figure 2, C and D). Cells can use diverse mech-
anisms to increase OXPHOS, however, it has been reported that 
antiinflammatory Mϕ use fatty acids to support OXPHOS (34). We 
therefore hypothesized that pResMϕ might use fatty acids to sup-
port their protumor phenotype and confirmed that fatty acid oxi-
dation was an important component of tumor-mediated increases 
in OXPHOS, as treatment with etomoxir reduced basal OCRs to 
levels observed in non–tumor-bearing mice (Figure 2, E and F).
Itaconic acid is the most highly upregulated metabolite in 
pResMϕ from tumor-bearing mice. Since Mϕ metabolism was sig-
nificantly increased by tumors, we next investigated whether 
altered metabolite levels in pResMϕ are associated with tumor 
promotion. Using untargeted profiling of primary metabolites 
in purified pResMϕ, we identified several metabolites that 
were significantly upregulated in B16 and ID8 tumor-bearing 
mice as compared with naive mice (Figure 3, A and B, respec-
tively). Among the most highly upregulated metabolites were 
lactic acid, previously implicated in Mϕ polarization (8), orni-
thine and polyamines such as putrescine, implicated in arginine 
metabolism and tumor promotion (35), and, somewhat sur-
prisingly, itaconic acid, which was the most highly upregulated 
metabolite (>15-fold). Itaconate accumulation is catalyzed by 
the enzyme encoded by Irg1 (20); accordingly, we found that Irg1 
mRNA expression was significantly upregulated in pResMϕ from 
mice bearing B16, 3LL, or MC38 tumors (Figure 3C) as well as 
in mice bearing ID8, IG10, or IF5 ovarian carcinomas (Figure 
3D). Ingenuity Pathway Analysis (IPA) (QIAGEN; https://www. 
qiagenbioinformatics.com/products/ingenuitypathway-analysis) 
of our metabolomics data confirmed not only that itaconate was 
the most highly upregulated metabolite but that several saturated 
fatty acids were also significantly downregulated (Table 1), con-
sistent with the association between itaconic acid production and 
similar between pResMϕ from control and tumor-bearing mice 
(Figure 1D and Supplemental Figure 1E).
Numerous studies have ascribed a protumor phenotype for 
tumor-associated Mϕ (4). Consistently, we found that specific 
depletion of peritoneal Mϕ (>90% depletion) 2 days after tumor 
inoculation resulted in a significantly reduced tumor burden (Fig-
ure 1E). We obtained similar results using Rag1–/– mice, indicating 
that the protumor effects were independent of T and B lympho-
cytes. Moreover, the reductions in tumor burden were indistin-
guishable when the clodronate-depleting agent was administered 
prior to tumor inoculation (day 0), suggesting that the pResMϕ 
populations present in naive mice already have tumor-promoting 
Figure 2. Tumors increase oxidative and glycolytic metabolism in 
pResMϕ. Extracellular flux analysis of F4/80-sorted pResMϕ from non–
tumor-bearing control mice or mice inoculated with B16 via the indicated 
routes were analyzed. The (A) OCR and (B) ECAR were graphed over time 
as indicators of OXPHOS and glycolysis, respectively. Drugs were injected 
into the ports at the indicated time points. F4/80-sorted pResMϕ from 
no–tumor-bearing control mice or mice bearing ID8 ovarian carcinoma (day 
47) were similarly evaluated for (C) cellular OCR and (D) ECAR. (E) OXPHOS 
of peritoneal Mϕ from control and B16 tumor–bearing mice were evaluated 
following injection of etomoxir into the first port at the indicated time 
point. (F) Basal OCRs for the treatment groups were graphed. **P < 0.01, by 
ANOVA with Tukey’s multiple comparisons test. All plots are representative 
of 3 experiments. Data represent the mean ± SEM. AA, Antimycin A.
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bled (Figure 4K) and Irg1 (Figure 4L) shRNA vectors transduced 
pResMϕ similarly (see also Supplemental Figure 2A) and that 
EGFP encoded by our vectors was not detected in tumor cells or 
any host cells other than pResMϕ. Additionally, we observed no 
differences in cytokine gene expression in pResMϕ transduced 
with Irg1 shRNA as compared with expression levels in the 
scrambled control (Supplemental Figure 2B). Although multiple 
metabolites were increased in tumor-bearing mice, knockdown 
of other metabolic enzymes, namely arginase 1 and lactate dehy-
drogenases A and B, did not affect tumor burden (Supplemental 
Figure 3). To complement the lentivirus-based approach, we also 
found that adoptive transfer of Irg1–/–, but not WT, pResMϕ into 
clodronate-depleted recipient mice resulted in a similarly sig-
nificant reduction of peritoneal tumor burden (Figure 4M). The 
adoptively transferred donor cells comprised more than 90% of 
the recovered pResMϕ in recipient mice, and equivalent yields of 
total pResMϕ were obtained from mice receiving cells from WT 
and Irg1–/– mice (Supplemental Figure 4). Taken together, these 
data demonstrate that tumor-induced Irg1 expression is required 
for pResMϕ-associated tumor promotion.
Irg1 in pResMϕ regulates OXPHOS. Knowing that itaconic acid 
can regulate OXPHOS and cell metabolism in other systems (13, 
18, 19), we next determined whether Irg1 shRNA treatment alters 
pResMϕ metabolism and whether those changes could be import-
ant for the control of tumors. Treatment of tumor-bearing mice 
with Irg1 shRNA reduced the basal and maximal OCRs of pResMϕ 
to levels comparable to those in non–tumor-bearing control mice 
(Figure 5, A and B). In contrast, we found that Irg1 shRNA had no 
effect on the basal OCR of pResMϕ from control mice.
We reasoned that reduced OXPHOS by pResMϕ in Irg1 shRNA–
treated mice could either be due to direct regulation by resulting 
itaconic acid or an indirect result of the lower tumor burden in these 
mice. To distinguish between these 2 possibilities, we increased the 
tumor dose to a level at which Irg1 shRNA treatment was no longer 
capable of reducing the tumor burden (Figure 5C). At this higher 
dose, however, we found that Irg1 shRNA was still capable of reduc-
ing Mϕ basal and maximal OCRs (Figure 5D). Thus, the reduced 
OXPHOS following Irg1 shRNA is not simply due to a reduced 
tumor burden but rather is a direct effect of the lack of Irg1.
Itaconic acid regulates mitochondrial ROS production in pResMϕ. 
Recent studies have shown ROS production to be a component of 
epithelial IRG1–mediated regulation of inflammation (24) and the 
antimicrobial properties of IRG1 in Mϕ lineage cells in a zebrafish 
model (23). Therefore, we sought to determine whether Irg1 could 
modulate ROS levels in pResMϕ in the context of tumor regulation. 
ROS levels were evaluated by several different means. First, we 
used the cell-permeant dye CM-H2DCFDA that detects hydroxyl, 
peroxyl, and other ROS within cells. Irg1 shRNA treatment sig-
nificantly reduced the median expression of CM-H2DCFDA 
in pResMϕ to levels observed in non–tumor-bearing mice (Fig-
ure 5E and Supplemental Figure 5A). Recognizing that CM- 
H2DCFDA, as a general oxidative stress indicator, has certain 
limitations (36), we also measured MitoSOX Red as a marker of 
superoxide specifically attributable to mitochondrial function. 
We consistently found that Irg1 shRNA treatment significantly 
reduced the median expression of MitoSOX Red to control lev-
els (Figure 5F and Supplemental Figure 5B). Furthermore, we 
fatty acid degradation (23). Western blotting confirmed IRG1 pro-
tein expression in pResMϕ from tumor-bearing mice, but IRG1 was 
not detected in B16 or ID8 tumor lysates, further confirming that 
the IRG1 expression in our system was due to the pResMϕ (Figure 
3E). In vitro, we observed that Irg1 expression was also upregulated 
in pResMϕ cocultured with B16 or ID8 tumor cells (Figure 3F). 
Interestingly, the ability of B16 tumor cells to induce Irg1 expres-
sion in pResMϕ was lost when the tumor cells were separated from 
the Mϕ by a Transwell insert, suggesting that cell-cell contact is 
important for B16-mediated Irg1 induction. In contrast, ID8 cells 
were still capable of inducing Irg1 expression in Transwell condi-
tions, indicating a distinct mechanism of Irg1 induction for these 
tumor cells that involved soluble factor(s) (Figure 3F). These data 
suggest that tumors elicit an accumulation of itaconic acid as a 
result of Irg1 expression in pResMϕ.
Irg1 silencing in pResMϕ reduces peritoneal tumor burden. To 
more directly delineate a possible role for itaconic acid in tumor 
progression, we used a lentiviral shRNA approach that specifi-
cally targets Irg1 expression in pResMϕ (3, 32). Injection of Irg1 
shRNA i.p. resulted in a significant reduction of Irg1 expression in 
F4/80-sorted pResMϕ (Figure 4A). Remarkably, Irg1 shRNA treat-
ment significantly reduced B16 tumor burden in the peritoneum, 
as determined by cell counting (Figure 4B) and MRI imaging of 
live tumor-bearing mice (Figure 4, C and D). Likewise, Irg1 shRNA 
significantly reduced ID8 ovarian carcinoma in the peritoneum 
(Figure 4, E and F). Although Irg1 targeting in pResMϕ had this 
profound effect, it did not alter the overall number of F4/80+ Mϕ 
recovered from the peritoneum (Figure 4G) or Gata6 expression 
by pResMϕ (Figure 4, H–J). Moreover, we confirmed that scram-
Table 1. IPA of the metabolomics data
Molecules Expression fold change
Itaconic acid ↑ 15.922
L-asparagine ↑ 11.363
2-oleoylglycerol ↑ 7.255
Thymidine ↑ 7.162
Thymine ↑ 7.156
Ethanolamine ↑ 6.905
L-alanylalanine ↑ 6.354
L-lysine ↑ 6.264
L-ornithine ↑ 5.996
(S)-2,4-diaminobutanoic acid ↓ –6.220
Octanoic acid ↓ –5.930
Decanoic acid ↓ –4.692
Dihydroxyacetone ↓ –4.554
1,5-anhydroglucitol ↓ –4.520
Lauric acid ↓ –2.649
1-palmitoylglycerol ↓ –1.786
Glutaric acid ↓ –1.629
Benzoic acid ↓ –1.518
Isomaltose ↓ –1.311
Unbiased metabolomic analysis was performed on F4/80-sorted pResMϕ 
from control and B16 melanoma–bearing mice. Each group contained at 
least 5 replicate samples. The data sets were analyzed using IPA software 
(QIAGEN) to obtain a list of the top-10 upregulated and downregulated 
molecules in the tumor-bearing group as compared with the control group.
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Nrf2, a key regulatory factor of antioxidant gene expression, as 
well as that of 7 of 10 other antioxidant genes was significantly 
downregulated in pResMϕ from Irg1 shRNA–treated mice (Figure 
5H). The levels of Nrf2 expression in pResMϕ from Irg1 shRNA–
treated tumor-bearing mice were comparable to those of pResMϕ 
from non–tumor-bearing control mice. Extracellular ROS lev-
els were significantly elevated in the peritoneal lavage fluid 
from tumor-bearing mice as compared with levels in fluid from 
control mice (Supplemental Figure 6A). Taken together, these data 
indicate that tumor-induced Irg1 expression promotes mitochon-
drial ROS levels and subsequent antioxidant activity in pResMϕ. 
Since ROS have been reported to induce cytokine expression and 
pResMϕ can be important sources of ROS, the lack of changes in 
their cytokine gene expression in these pResMϕ in the context of 
changing ROS levels (Supplemental Figure 2B) was somewhat 
surprising. Our metabolomic data analysis revealed that pResMϕ 
have significantly higher amounts of glutathione as compared 
with bone marrow–derived Mϕ, which may partly protect them 
from such ROS-mediated effects (Supplemental Figure 6B).
Itaconic acid–mediated ROS in pResMϕ regulate MAPK activa-
tion in tumor cells. We next sought to mechanistically link tumor- 
induced, Irg1-dependent Mϕ ROS levels with tumor promotion. 
Although ROS have well-described antitumor effects in some 
settings, it has also been shown to activate pathways promoting 
tumor growth (25, 28). We found that specific Irg1 knockdown in 
pResMϕ signifi cantly reduced the levels of phosphorylated ERK 
(p-ERK) in peritoneal B16 tumors (Figure 6A). We also found that 
clodronate-mediated removal of pResMϕ reduced p-ERK levels 
to a similar degree in peritoneal tumors (Figure 6B). Treatment of 
tumor-bearing mice with the antioxidant N-acetylcysteine (NAC) 
significantly reduced p-ERK levels in tumor lysates (Figure 6C) and 
the peritoneal tumor burden (Figure 6D). Furthermore, p-ERK was 
significantly elevated in B16 tumor cells cocultured in vitro with WT, 
but not Irg1–/–, pResMϕ (Figure 6E), and treatment of B16 and ID8 
tumors with PD98059, a selective inhibitor of the MAPK cascade, 
significantly inhibited tumor cell proliferation (Supplemental Fig-
ures 6, C and D). Taken together, these findings suggest that tumor- 
induced Irg1 and subsequent itaconic acid regulate peritoneal 
tumors, at least in part, through alterations in Mϕ-specific ROS.
Expression of Irg1 in monocytes associated with human peri-
toneal tumors. Having established a paradigm whereby tumor- 
induced Irg1 in pResMϕ results in fatty acid–mediated increases 
in ROS that in turn activate tumor cells in mice, we asked whether 
IRG1 expression might be detected in human ovarian cancers. To 
that end, we isolated the cellular components from the peritoneal 
ascites fluid of 8 women with ovarian carcinoma and assayed for 
the expression of IRG1. In parallel, we assayed these samples for 
CD14+ monocytes by flow cytometry. We observed a significant 
association between the number of CD14+ monocytes in each 
bulk cell sample and IRG1 levels, suggesting that these cells were 
expressing IRG1 (Figure 7A). Consistent with that notion, we 
found that IRG1 expression was significantly (P < 0.05) elevated 
in isolated monocytes from all 11 patients as compared with expres-
sion levels in non-monocyte cell fractions (Figure 7B). Furthermore, 
IRG1 expression was significantly elevated in CD14+ monocytes 
isolated from patients’ ascites as compared with blood circulating 
monocytes from either healthy individuals or patients (Figure 7C). 
detected increased CM-H2DCFDA levels when pResMϕ from 
naive WT mice were cocultured in vitro with either B16 or ID8 
tumor cells, but not when pResMϕ from Irg1–/– mice were used 
(Figure 5G and Supplemental Figure 5C). Changes in ROS pro-
duction were further confirmed by analyzing the expression of 
11 antioxidant genes whose expression is tied to ROS levels (37). 
By quantitative PCR (qPCR), we found that the expression of 
Figure 3. Irg1 and itaconic acid are upregulated in pResMϕ by peritoneal 
tumors. Unbiased metabolomic analysis was performed on F4/80-sorted 
pResMϕ from control and either (A) B16 melanoma– or (B) ID8 ovarian 
carcinoma–bearing mice. The mean values from at least 5 replicate 
samples were log10 transformed and plotted (P < 0.05 for all metabolites 
by unpaired Student’s t test). Irg1 gene expression was evaluated by qPCR 
in F4/80-sorted pResMϕ from control mice and mice bearing either (C) 
day-9 B16 melanoma, 3LL, or MC38 tumors or (D) day-30 ID8, IG10, or IF5 
ovarian carcinomas. Triplicate samples were evaluated, with one of the 
no-tumor control samples serving as the 1.0 relative reference point.  
**P < 0.01, by unpaired Student’s t test. (E) IRG1 protein levels in B16  
and ID8 tumor lysates and pResMϕ purified from tumors were determined 
by Western blotting. Unstimulated or LPS-stimulated bone marrow–
derived Mϕ from WT and Irg1–/– mice were used as controls. (F) pResMϕ 
were cocultured in vitro with the indicated tumor cells for 48 hours. Irg1 
expression was evaluated by qPCR (n = 3). cocx, co-culture.  **P < 0.01 
and ****P < 0.0001, by ANOVA with Tukey’s multiple comparisons test. 
Data represent the mean ± SEM.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
3 7 9 9jci.org   Volume 128   Number 9   September 2018
Figure 4. Irg1 silencing in pResMϕ reduces peritoneal tumor burden. B16 tumor–bearing mice were treated with lentiviral shRNA (scrambled control or Irg1 
silencing). (A) Gene expression of Irg1 was evaluated by qPCR (n = 9). (B) B16 tumor burden was quantitated and (C) evaluated by MRI of live tumor-bearing mice 
(MRI images are representative of 8 mice). (D) Tumor volumes were calculated by computing the tumor area on each plane and multiplying by the thickness of 
each slice (n = 8). The tumor weight (E) and volume (F) of ID8 ovarian carcinoma–bearing mice were measured (n ≥5). (G) Total numbers of F4/80+ pResMϕ were 
comparable among 6 scrambled shRNA and Irg1 shRNA recipient mice. Gata6 gene expression by qPCR (H) and protein levels were indistinguishable among 
scrambled (I) and Irg1 (J) shRNA recipient mice. A similar uptake of lentiviral shRNA was confirmed by EGFP visualization in F4/80+ pResMϕ isolated from mice 
receiving scrambled (K) or Irg1 (L) shRNA constructs. All FACS plots are representative of at least 6 mice per group. (M) Clodronate-depleted CD45.1 congenic 
mice (5 mice/group) were inoculated i.p. with peritoneal lavage cells from WT or Irg1–/– mice 1 day prior to tumor inoculation, and the B16 tumor burden was 
quantitated. Data represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by Mann-Whitney U test.
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IRG1 protein was detected in CD14+ monocytes from patients with 
ovarian carcinoma, but not in normal peripheral blood mononuclear 
cells (PBMCs) (Figure 7D). These data suggest that myeloid cells 
associated with human ovarian cancers express IRG1, which posi-
tions them to promote tumor growth through itaconate production.
Discussion
We show for the first time to our knowledge that itaconic acid is a 
critical metabolic component underlying the crosstalk between 
tumors and tumor-associated Mϕ. Itaconic acid levels were dra-
matically upregulated in pResMϕ from tumor-bearing mice, and 
Figure 5. Itaconate regulates OXPHOS and mito-
chondrial ROS expression in pResMϕ. Extracel-
lular flux was analyzed on F4/80-sorted pResMϕ 
from B16 tumor–bearing mice receiving either 
scrambled or Irg1 shRNA (A). The OCR over time 
(A) and the basal OCR (B) were graphed. Data are 
representative of 3 experiments. **P < 0.01, by 
ANOVA with Tukey’s multiple comparisons test. 
Tumor burden (C) and pResMϕ extracellular flux 
(D) were evaluated in mice that received 1 × 105 
or 5 × 105 B16 tumor cells and either scrambled or 
Irg1 shRNA (n = 5).  **P < 0.01, by ANOVA with 
Tukey’s multiple comparisons test. pResMϕ 
ROS production was assessed by measuring the 
median CM-H2DCFDA (E) and MitoSOX Red (F) 
expression by flow cytometry (n = 6).  *P < 0.05 
and **P < 0.01, by ANOVA with Tukey’s multiple 
comparisons test. (G) pResMϕ from WT or Irg1–/– 
mice were cocultured in vitro with the indicated 
tumor cells for 48 hours. Median CM-H2DCFDA 
expression was evaluated by flow cytometry  
(n = 3). The dotted line denotes no DCFDA control 
staining. *P < 0.05 and ***P < 0.001, by ANOVA 
with Tukey’s multiple comparisons test. (H) 
Gene expression levels modulated by oxidative 
stress and ROS in mice that received scrambled 
or Irg1 shRNA were evaluated by qPCR (n = 14). 
*P < 0.05, **P < 0.01, and ***P < 0.001, by 
Mann-Whitney U test. Data represent the  
mean ± SEM.
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neal cancer treatment. The upregulation of OXPHOS by tumor- 
promoting itaconate was highly localized, since inoculation of 
mice with tumors at distant sites did not increase the pResMϕ 
OCRs or ECARs, and coculture experiments revealed a cell-
cell contact requirement for promotion of itaconate production. 
Itaconate production was the only metabolic pathway we tested 
that was capable of significantly regulating tumor burden. Irg1 
expression has been reported in several cell types (24, 38–40), but 
in the peritoneal cavity, it is Irg1 expression by resident Mϕ that 
promotes tumor growth. It is possible that blood-borne cells enter 
the peritoneal cavity and take on the resident phenotype, however, 
our data indicate that infected pResMϕ remained over the course of 
the experiment. Although we could not directly examine the resident 
Mϕ population of patients with advanced cancer, IRG1 expression in 
patients’ monocytes from tumor ascites suggests that this metabolite 
could be important in the progression of ovarian carcinoma.
Itaconic acid is emerging as an important regulator of Mϕ 
metabolism and effector function. The mechanisms by which 
tumors induce Irg1 and itaconic acid remain unclear and war-
rant further investigation. Irg1 induction was still observed when 
TNF-, IFN-γ-, IL-6-, or TLR4-KO mice were inoculated with 
tumors, however, we could not rule out the possibility that 
tumor-derived cytokines influence pResMϕ. One possibility may 
be the induction of hemoxygenase-1, a stress protein recently 
shown to induce Irg1, which may be associated with tumors and 
tumor-associated Mϕ (41, 42). Once upregulated, itaconic acid 
is accompanied by increases in fatty acid–driven OXPHOS. This 
appears to be in contradiction to the succinate dehydrogenase- 
inhibitory role ascribed to itaconic acid (18, 19). However, 
OXPHOS is principally driven by NADH recycling, which can be 
fueled through succinate dehydrogenase–independent mecha-
nisms, such as the mitochondrial citrate and malate shuttles (43), 
which may operate differently in the presence of tumor. Our find-
ings are consistent with those of Hall et al., who showed that Irg1 
depletion impaired fatty acid oxidation in Mϕ-lineage cells (23). 
Moreover, we found that upregulated itaconic acid in pResMϕ 
from tumor-bearing mice was associated with reduced levels 
of several long-chain fatty acids. Their oxidation may help fuel 
increases in OXPHOS that comprise a major source of cellular 
ROS (23, 44). Thus, itaconate is clearly important for the regula-
tion of intracellular and extracellular ROS production in pResMϕ. 
ERK activation in tumor cells is probably one of many pathways 
activated by ROS that could potentially regulate tumor growth in 
vivo. We never detected Irg1 expression in tumor cells, and if Irg1 
expression is relatively Mϕ specific, then targeting Irg1 levels in 
the peritoneum may be a means to regulate pResMϕ-derived ROS 
without eliciting some of the side effects associated with systemic 
ROS inhibition.
Several lines of evidence support the hypothesis that 
pResMϕ, rather than newly migrated inflammatory monocytes, 
mediate the Irg1-mediated protumor effects. We administered 
lentiviral constructs 1 week prior to tumor inoculation, thus 
limiting metabolic programming before any tumor-mediated 
alterations in leukocyte populations could occur. Importantly, 
these infected Mϕ were labeled with EGFP, which remained 
with this Gata6+ cell population throughout our tumor stud-
ies. Thus, our alterations of itaconate production were 
this metabolite acts as a critical regulator of Mϕ metabolism, ROS 
production, and tumor progression, as shown in our study. Irg1 
expression was induced in pResMϕ by 6 cancer cell lines, includ-
ing 3 different ovarian carcinoma cell lines. Our data expand on 
the importance of metabolic alterations in the tumor microen-
vironment and identify itaconate as a potential target for perito-
Figure 6. pResMϕ regulate MAPK activation in peritoneal tumors via 
itaconate and ROS. B16 tumor lysates were prepared as described in Meth-
ods and analyzed by Western blotting for expression of p-ERK and total 
ERK. (A) Tumor lysates from mice that received scrambled or Irg1 shRNA 
constructs were compared (n ≥4). *P < 0.05, by Mann-Whitney U test. (B) 
Tumor lysates from mice that received control or clodronate liposomes 
were compared. *P < 0.05, by Mann-Whitney U test. (C) Tumor lysates 
from saline control– or NAC-treated mice were analyzed (n = 5). *P < 0.05, 
by Mann-Whitney U test. (D) NAC i.p. treatment reduced the number of 
B16 tumor cells (n = 10). **P < 0.01, by Mann-Whitney U test. (E) B16 tumor 
cells were cultured in vitro alone or in coculture with the indicated pResMϕ. 
After 48 hours, tumor cells, gated by CD146+F4/80– expression, were ana-
lyzed by flow cytometry for intracellular p-ERK expression. *P < 0.05 and 
**P < 0.01, by ANOVA, corrected for multiple comparisons. Data represent 
the mean ± SEM.
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and host cellular responses at differing ratios between Mϕ and 
tumor burden levels so that the targeting of this metabolite for 
degradation becomes a potential means by which peritoneal 
tumors and perhaps other diseases can be treated.
Methods
Mice. WT C57Bl/6 and CD45.1 (Ptprca) mice were obtained from The 
Jackson Laboratory and bred at the NCI’s Frederick Cancer Research 
and Development Center. Irg1–/– mice were obtained from Michael 
Diamond (Washington University School of Medicine, St. Louis, Mis-
souri, USA). Mice were used at 8 to 10 weeks of age, and female mice 
were used for ovarian carcinoma studies.
Isolation of peritoneal Mϕ. Peritoneal exudate cells were isolated 
by injecting 5 ml sterile PBS into the peritoneal cavity, gently mas-
saging the anesthetized mouse, and slowly withdrawing the fluid. Mϕ 
contained within the exudate fluid were purified using biotinylated 
anti-F4/80 antibody (clone BM8; BioLegend) and magnetic bead sep-
aration (Miltenyi Biotec). Cells were counted using a Sysmex XP-300 
(Roche Diagnostics).
Cell lines. B16 melanoma, 3LL, and MC38 cell lines were obtained 
from the American Type Culture Collection (ATCC). The murine 
ovarian surface epithelial cell lines MOSEC-ID8, IG10, and IF5 were 
obtained from Katherine Roby (University of Kansas Medical Center, 
Kansas City, Kansas, USA) and grown as described previously (49). All 
cell lines were confirmed to be free of mycoplasma contamination. 
Cells were propagated in DMEM supplemented with 10% FBS and 
L-glutamine. An in vivo–passaged ID8 cell line that could be reintro-
duced into naive mice was generated by injecting mice with 1 × 105 ID8 
cells and then collecting and centrifuging the resulting ascites fluid on 
approximately day 80 (50). For tumor cell–Mϕ coculture experiments, 
5 × 105 peritoneal Mϕ and tumor cells were mixed (1:1) and incubated 
in 6-well plates for 48 hours. In some experiments, tumor cells were 
seeded on Transwell inserts containing 3-μM pores (Costar). In some 
experiments, tumor cells were treated with the MAPK inhibitor 
PD98059 (50 μM; Cell Signaling Technology), and cell proliferation 
specifically targeted to pResMϕ, with results consistent with 
our previous findings (3, 32). Therefore, pResMϕ specifically 
facilitate tumor progression in the peritoneum, in large part by 
tumor-mediated increases in itaconate production. It is becom-
ing increasingly important to understand the regulation of 
itaconic acid expression in diverse Mϕ subsets. Since myeloid- 
derived suppressor cells (MDSCs), a heterogeneous population 
of tumor-associated Mϕ, utilize fatty acid oxidation to support 
their ROS production and immunosuppressive phenotype (45), 
it will be interesting to study metabolic changes in MDSC pop-
ulations and determine whether targeting itaconic acid might 
regulate MDSC-associated ROS and MDSC-suppressive poten-
tial. Future studies aimed at elucidating the regulation of Irg1 
expression in myeloid cells of different anatomical compart-
ments are warranted.
The identification of itaconic acid as an important regulator 
of pResMϕ function raises the intriguing question of how this 
might be used therapeutically for the control of ovarian and peri-
toneal tumors. Our results indicate that tumor burden is likely 
to be an important factor in dictating the success of IRG1-based 
therapies and that early intervention is important, since Irg1 
intervention was effective at lower, but not higher, tumor bur-
dens. The importance of itaconic acid as an inhibitor of meta-
bolic pathways such as those for isocitrate lyase in bacteria and 
glycolysis in mammals may yield important clues for its devel-
opment as a therapeutic target. Irg1-deficient Mϕ have impaired 
bactericidal capabilities, and certain pathogenic bacteria, such 
as Yersinia pestis and Pseudomonas aeruginosa, degrade itaconate 
as a survival mechanism (46). Itaconate metabolism occurs via 
enzymes that convert itaconate into pyruvate and acetyl-CoA. 
Mammals have similar mechanisms for degrading itaconate 
(47) that are probably a means to counteract itaconate-mediated 
inhibition of glycolysis (48). Our data identify itaconic acid as a 
potential therapeutic target and support the need for additional 
research into the multitude of ways itaconate regulates tumor 
Figure 7. IRG1 is expressed in monocytes associated with human peri-
toneal tumors. IRG1 expression was evaluated by qPCR using total RNA 
isolated from cell fractions from 11 human patients with ovarian carcinoma. 
(A) IRG1 expression levels were established by setting normal PBMC values 
to 1.0, and the relative levels in ascites monocytes were graphed in relation 
to the total number of CD45+CD14+ monocytes in each sample. Linear 
regression analysis was performed (GraphPad Prism) to obtain the best 
curve fit (r2 = 0.93; P < 0.0001). (B) The fold difference in IRG1 expression 
among monocytes and non-monocyte fractions is shown. CD14+ monocytes 
were purified as described in Methods. For each patient sample, the level 
of IRG1 expression in the non-monocyte fraction was set to 1.0, and the 
relative level of IRG1 expression in the corresponding monocyte fraction 
was graphed (log10). Significance was determined by a 1-sample Student’s t 
test using 1.0 as a theoretical mean (P < 0.05). (C) IRG1 expression levels in 
CD14+ PBMCs isolated from 6 healthy volunteers and 5 patients were com-
pared with IRG1 levels in the 11 ascites samples. *P < 0.0 and **P < 0.01, 
by ANOVA corrected for multiple comparisons. (D) IRG1 protein expression 
in CD14+ monocytes isolated from healthy blood and patients’ ascites was 
analyzed by Western blotting.
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mm. A fat suppression technique, spectral presaturation with inversion 
recovery (SPIR), was used to suppress the fat component in the images 
and thus to help distinguish fat from tumor tissue in the peritoneal 
cavity. The MRI methodology described generates high-resolution 
T2w images with a clear contrast between the tumor mass and the 
peritoneal organs and allows post-imaging analysis for a quantitative 
assessment of tumor burden.
Primary metabolite analysis. Magnetically sorted peritoneal Mϕ 
(5.0 × 106 to 7.5 × 106) were pelleted and snap-frozen in liquid nitrogen. 
Samples were further processed and analyzed for untargeted primary 
metabolites by the West Coast Metabolomic Center (UCD, Davis, Cal-
ifornia, USA). Mass spectrometric gas chromatography–time of flight 
(GC-TOF) analysis was performed using the Agilent GC 6890/LECO 
Pegasus III instrument. Samples were normalized using the sum of 
the peak heights for all identified metabolites. Metabolite data were 
analyzed using IPA.
Extracellular flux analysis. Magnetically sorted resident Mϕ 
were seeded at 1.0 × 106 (24-well) or 0.3 × 106 (96-well) cells per 
well in complete media (+0.5 μM retinoic acid, +20 ng/ml M-CSF) 
and incubated for 2 hours. Plated cells were washed gently with 
PBS and incubated with Seahorse Bioscience assay media supple-
mented with 2 mM glutamine and 25 mM glucose (+0.5 μM retinoic 
acid, +20 ng/ml M-CSF) for 1 hour at 37°C with no CO2. Extracel-
lular flux analysis was performed at 37°C with no CO2 using the 
XF-24 or XF-96 analyzer (Seahorse Bioscience) according to the 
manufacturer’s instructions. Port additions and times were used as 
indicated in the figures.
Flow cytometric analysis. Cells (1 × 106) were incubated for 15 
minutes in cell-staining buffer (0.1% BSA, 0.1% sodium azide) con-
taining 250 μg/ml 2.4G2 ascites. In some experiments, cells were 
incubated with 5 μM CM-H2DCFDA or MitoSOX Red mitochondrial 
Superoxide Indicator (Invitrogen, Thermo Fisher Scientific) for 20 
minutes at 37°C. Cells were stained with fluorescently conjugated 
antibodies (F4/80 antibody clone BM8; CD49f antibody clone GoH3; 
Ly6C antibody clone AL-21; BD Pharmingen) for 20 minutes. For 
intracellular staining, surface-labeled cells were fixed and permeabi-
lized (Invitrogen, Thermo Fisher Scientific) and incubated with Gata6 
antibody (clone D61E4; Cell Signaling Technology) or p-ERK1/2 
(Thr202/Tyr204) antibody (clone 4B11B69; BioLegend). After wash-
ing, the labeled cells were analyzed on an LSR II Flow Cytometer using 
FACSDIVA software (BD Biosciences).
qPCR. Total RNA was isolated using a High Pure RNA Isolation 
Kit (Roche Diagnostics). RNA was reverse transcribed using the High 
Capacity cDNA Archive Kit (Applied Biosystems). Genes of interest 
were examined by gene expression assays (Applied Biosystems). 
Briefly, 10 ng cDNA was placed into a final volume of 20 μl contain-
ing 10 μl TaqMan Universal PCR Mix (Applied Biosystems, Thermo 
Fisher Scientific) and 1 μl primer/probe gene expression assay. All 
samples were run on an ABI 7300 Real-Time PCR system and ana-
lyzed using the ΔΔCt method (53). Gene expression was normal-
ized to levels of the housekeeping gene HPRT.
Western blot analysis. Purified monocytes and Mϕ were lysed 
in RIPA buffer. Tumors were homogenized in RIPA buffer using a 
GentleMACS Tissue Dissociator (Miltenyi Biotec). Total protein was 
quantitated by bicinchoninic acid assay (Thermo Fisher Scientific). 
Total protein (10–20 μg/lane) was separated by SDS-PAGE and trans-
ferred to PVDF membranes (Invitrogen, Thermo Fisher Scientific). 
was quantified using the CellTiter Aqueous Non-Radioactive Cell 
Proliferation Assay (Promega).
Isolation of human samples. Peripheral blood leukocytes were iso-
lated from healthy individuals and patients with ovarian carcinoma 
using Lymphocyte Separation Medium (Lonza). The ascites samples 
were centrifuged at 3,000 g for 10 minutes to remove the noncellular 
ascites fluid. Red blood cells were lysed by incubating the cell pellet 
in ammonium chloride potassium (ACK) lysing buffer for 10 minutes. 
Cells were washed with PBS and cryopreserved until use. Upon thaw-
ing, the cells were counted using a Sysmex XP-300 and analyzed by 
flow cytometry. The number of monocytes in each bulk cell fraction 
was determined by multiplying the total number of cells by the per-
centage of CD45+CD14+ cells (CD45 antibody clone HI30, CD14 anti-
body clone M5E2; BioLegend). In some experiments, monocytes were 
isolated using antibodies against CD14 and magnetically coupled 
beads (Miltenyi Biotec). Total RNA and cDNA used for qPCR analyses 
were prepared as described below.
Lentiviral shRNA generation. The In-fusion Cloning Kit (Clon-
tech Laboratories) was used to modify the previously described pHR′ 
SIN-cPPT-SEW plasmid (51). Lentiviral particles were produced by 
transfecting 293-T cells with lentiviral plasmid and helper constructs 
(52) (pCMV-Δ8.91 [GAG/POL, Tat and Rev] and pMD2.G [VSV-G 
coat]) using X-tremeGENE 9 Transfection Reagent (Sigma-Aldrich). 
Lentivirus was concentrated using the Lenti-X Concentrator Kit 
(Clontech) with supernatants from 293T cells 48 hours after transfec-
tion. Lentiviral particles were resuspended in PBS and stored at –80°C. 
Mice were injected i.p. 7 days prior to tumor cell injections (day –7) 
with 200 μl concentrated lentiviral particles.
In vivo tumor model. Mice were injected i.p. with 1 × 105 tumor 
cells in 100 μl sterile saline. Some mice received 100 μl control or 
clodronate liposomes i.p. (clodronateliposomes.org) or 150 
mg/kg NAC (Sigma-Aldrich) via the drinking water. Peritoneal 
lavages were done on day 9 unless otherwise indicated. For the 
adoptive transfer experiment, peritoneal lavage exudate cells 
from 10 WT or Irg1–/– mice were injected i.p. into clodronate- 
depleted, CD45 congenic mice 1 day prior to tumor inocu-
lation. For quantitation of B16 melanoma cells, the tumors 
throughout the peritoneal cavity were surgically dissected, 
passed through Filtra-Bags (Labplas) and 100-μM nylon filters 
(Thermo Fisher Scientific), and the resulting single-cell suspension 
was counted on a Cellometer Auto T4 (Nexcelom Bioscience). For the 
in vivo–passaged ID8 tumor model, tumors were weighed and mea-
sured using calipers. Extracellular ROS contained within peritoneal 
lavage fluid was measured using the Amplex Red Hydrogen Peroxide/ 
Peroxidase Assay Kit (Thermo Fisher Scientific).
In vivo MRI. The MRI experiments were conducted using a 3.0T 
Intera Achieva Clinical Scanner (Philips) equipped with a 40-mm- 
diameter solenoid receiver coil (Philips Research) to detect the 
initial point of the peritoneal tumor growth and monitor its progres-
sion over time.
A multislice, T2-weighted turbospin echo (T2w-TSE) imaging 
sequence was applied in the coronal direction with a field of view 
(FOV) of 50 × 30 × 12 mm to cover the mid-part of the abdominal 
area. To minimize motion-induced artifacts in the resulting image, a 
respiratory triggering technique was used. The images were obtained 
with a repetition time (TR) of 5333 ms, an echo time (TE) of 80 ms, an 
in-plane resolution of 0.180 × 0.180 mm, and a slice thickness of 0.5 
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